| Title |
A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities
|
|---|---|
| Published in |
Drug Design, Development and Therapy, August 2018
|
| DOI | 10.2147/dddt.s166373 |
| Pubmed ID | |
| Authors |
Yue Liu, Yanlan Wang, Jieyu Xing, Yumei Li, Jiayu Liu, Zhong Wang |
| Abstract |
Interleukin-15 (IL-15) is an immunomodulatory cytokine. It can activate and expand cytotoxic CD8 T lymphocytes and natural killer cells, leading to potent antitumor effects. Various forms of IL-15 are now in different stages of development for cancer immunotherapy. One of the major issues with IL-15 or IL15-IL15Rα fusion is high toxicity due to systemic activation of immune cells. In this study, we engineered a nanobody-cytokine fusion molecule, anti-CEA-IL15, in which an anti-CEA nanobody was linked to an IL15Rα-IL15 fusion. The nanobody-cytokine fusion exhibited multiple mechanisms to kill tumor cells, including promoting immune cell proliferation and directing antibody-dependent cytotoxicity against CEA-positive tumor cells. In xenograft models, anti-CEA-IL15 was localized in the tumor microenvironment and exhibited more potent antitumor activities than non-targeting IL-15, supporting potential application of this multifunctional fusion molecule in tumor immunotherapy. We generated and validated a tumortargeting fusion protein, anti-CEA-IL15, which has potent cytokine activity to activate and mobilize the immune system to fight cancer cells. Such strategies may also be applied to other cytokines and tumor-targeting molecules to increase antitumor efficacy. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 30 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 30% |
| Student > Bachelor | 5 | 17% |
| Student > Ph. D. Student | 5 | 17% |
| Other | 2 | 7% |
| Student > Master | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 8 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Immunology and Microbiology | 7 | 23% |
| Biochemistry, Genetics and Molecular Biology | 5 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Engineering | 2 | 7% |
| Agricultural and Biological Sciences | 2 | 7% |
| Other | 4 | 13% |
| Unknown | 8 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 August 2022.
All research outputs
#8,008,078
of 25,498,750 outputs
Outputs from Drug Design, Development and Therapy
#544
of 2,273 outputs
Outputs of similar age
#127,117
of 342,157 outputs
Outputs of similar age from Drug Design, Development and Therapy
#17
of 69 outputs
Altmetric has tracked 25,498,750 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 2,273 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,157 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.
We're also able to compare this research output to 69 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.